As GLP-1 has a very short half-life, the GLP-1 receptor agonists (GLP1RAs) which had longer half-lives have been developed for treating T2DM and other metabolic diseases including obesity and liver diseases (Andersen et al., 2018). This evidence concerns the gene GCG and type 2 diabetes mellitus.